华兰疫苗(301207.SZ)发布前三季度业绩，归母净利润1.32亿元，下降50.51%

Core Viewpoint - Hualan Vaccine (301207.SZ) reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters was 806 million yuan, a year-on-year decrease of 15.81% [1] - The net profit attributable to shareholders was 132 million yuan, reflecting a year-on-year decrease of 50.51% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 86.26 million yuan, down 56.02% year-on-year [1] - Basic earnings per share were 0.2224 yuan [1]